CytomX Therapeutics, Inc. Stock Analysis & AI Score
CytomX Therapeutics, Inc. (CTMX) has an ST Score of 49.5 (C+), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $8.50 price target (+209.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
CytomX Therapeutics, Inc. (CTMX) has an ST Score of 49.5 (C+), driven by its Forecast (A) and held back by its Momentum (D+). Analysts rate it Buy with a $8.50 price target (+209.1% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD+
All factor grades
- ForecastA
- Financial StrengthA-
- ProfitabilityB+
- ValuationC+
- GrowthC-
- MomentumD+
- Piotroski1/9
Contact
CTMX stock: frequently asked questions
What is CTMX's ST Score?
CytomX Therapeutics, Inc. (CTMX) has an ST Score of 49.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CTMX a buy, hold, or sell?
Analysts rate CTMX a Buy, with a price target of $8.50 (+209.1% vs the current price). Our ST Score grades it C+ (49.5/100). The ST Score is a data-driven signal, not a recommendation.
What are CTMX's factor grades?
Valuation C+, Profitability B+, Financial Strength A-, Momentum D+, Growth C-, Forecast A.
What is CTMX's valuation grade?
CytomX Therapeutics, Inc. (CTMX) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CTMX's growth grade?
CytomX Therapeutics, Inc. (CTMX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CTMX's profitability grade?
CytomX Therapeutics, Inc. (CTMX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CTMX's financial strength grade?
CytomX Therapeutics, Inc. (CTMX) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CTMX?
The average analyst price target for CytomX Therapeutics, Inc. (CTMX) is $8.50 from 21 analysts, which is +209.1% versus the recent price of $2.75.
What is CTMX's Piotroski score?
CytomX Therapeutics, Inc. (CTMX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.